Dechert Survey of Securities Fraud Class Actions Brought Against U.S. Life Sciences Companies
March 20, 2013
The past year was another noteworthy one with respect to securities fraud class action lawsuits against life sciences companies. There was a meaningful increase in the number of securities fraud lawsuits and a continued emphasis on industry-specific allegations of material misstatements and omissions. Although life sciences companies continue to enjoy relative success in obtaining early dismissals of these cases, the large-scale risks that follow from a securities fraud class action will only be magnified by a recent U.S. Supreme Court decision regarding class certification.
David A. Kotler’s annual Dechert Survey of Securities Fraud Class Actions Brought Against U.S. Life Sciences Companies examines these developments and what the future may hold for life sciences companies in the securities fraud arena.